Mexico Patient Derived Xenografts/PDX Models Market (2025-2030)
The Mexico Patient Derived Xenografts/PDX Models Market was valued at $1.26 Million in 2025 and projected to reach to $1.73 Million by 2030, representing a compound annual growth rate of 6.5%. Mexico's PDX models market is positioned for steady growth as the country strengthens its position in preclinical oncology research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico Patient Derived Xenografts/PDX Models Market Trends and Insights
- Mexico is emerging as a growing hub for preclinical oncology research, with increasing adoption of PDX models among academic institutions and contract research organizations (CROs) seeking to improve drug development pipelines.
- The market in Mexico reflects broader Latin American trends toward personalized medicine and precision oncology, though penetration remains lower than in developed markets. Driving growth in Mexico are rising investments in cancer research infrastructure, collaborations between Mexican research centers and international pharmaceutical companies, and growing awareness of PDX models' superiority over traditional cell-line approaches.
- Mexico's strategic position in the Americas and cost-competitive research services are attracting multinational biotech firms to establish or expand PDX capabilities.
- Between 2025 and 2030, Mexico is expected to see incremental adoption across oncology research, supported by government initiatives and private sector partnerships focused on advancing drug discovery and development..
Key Market Statistics
- CAGR (2025-2030) 6.5% CAGR
- Market Size, 2025 ~USD 1.26 Million
- Forecast, 2030 ~USD 1.73 Million
- Country Mexico
Mexico Patient Derived Xenografts/PDX Models Market Overview
Market Valuation :
Mexico's PDX models market is valued at USD 1.26 million in 2025, with projected growth to USD 1.73 million by 2030, representing a steady CAGR of 6.5%.
Growing Research Hub :
Mexico is emerging as a key hub for preclinical oncology research, with increasing adoption of PDX models among academic institutions and contract research organizations seeking advanced drug development solutions.
CRO Expansion :
Contract research organizations in Mexico are increasingly integrating PDX models into their service portfolios to meet growing demand from pharmaceutical companies conducting oncology research.
Academic Adoption :
Mexican academic institutions are investing in PDX technology infrastructure to enhance their research capabilities and attract international collaborations in cancer drug development.
Mexico Patient Derived Xenografts/PDX Models Market Dynamics
- The adoption of patient-derived xenograft models among CROs and academic institutions is accelerating, driven by the need for more predictive preclinical models and cost-effective research solutions.
- Mexico's growing pharmaceutical research ecosystem and proximity to North American markets create favorable conditions for market expansion. The 6.5% CAGR reflects Mexico's gradual but consistent investment in advanced research infrastructure and increasing partnerships with international pharmaceutical companies.
- While growing slower than the global market (12.5% CAGR), Mexico's PDX market benefits from rising awareness of personalized medicine approaches and the country's competitive advantages in contract research services..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Mexico's PDX models market is valued at USD 1.26 million in 2025 and will reach USD 1.73 million by 2030, growing at 6.5% CAGR.
- Mexico is positioning itself as a cost-competitive preclinical research destination, attracting international pharmaceutical and biotech partnerships.
- Academic institutions and CROs in Mexico are increasingly adopting PDX models to enhance oncology drug development and personalized medicine capabilities.
- Government support and private sector investment in cancer research infrastructure are key drivers of PDX market expansion in Mexico through 2030.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Mexico Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.34 | 0.36 | 0.39 | 0.41 | 0.44 | 0.46 | 0.49 | 0.52 | 6.1 |
| CROS & CDMOS | 0.23 | 0.24 | 0.26 | 0.27 | 0.29 | 0.3 | 0.32 | 0.34 | 5.7 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 0.72 | 0.77 | 0.83 | 0.9 | 0.96 | 1.03 | 1.1 | 1.17 | 7 |
| TOTAL | 1.29 | 1.38 | 1.47 | 1.58 | 1.69 | 1.8 | 1.91 | 2.03 | 6.6 |
Target Audience
- Pharmaceutical Companies : Pharmaceutical firms seeking to outsource preclinical oncology research to Mexico-based CROs need market intelligence on local capabilities, pricing, and regulatory environment for PDX model services.
- Contract Research Organizations : Mexican and international CROs expanding PDX service offerings require market data to assess demand, competitive positioning, and growth potential within Mexico's emerging research ecosystem.
- Academic Institutions : Mexican universities and research centers investing in PDX infrastructure need market insights to justify investments, identify collaboration opportunities, and benchmark their capabilities.
- Biotech Investors : Venture capital and private equity firms evaluating investment opportunities in Mexico's life sciences sector need market analysis to assess growth potential and risk factors in PDX research.
- Healthcare Consultants : Management consulting firms advising clients on Latin American market expansion require Mexico-specific PDX market data to develop comprehensive regional strategy recommendations.
Key Companies in the Mexico Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Market Entry Strategy : Gain detailed insights into Mexico's PDX market dynamics to develop targeted market entry strategies and identify key partnerships with local CROs and academic institutions.
- Competitive Positioning : Understand Mexico's market landscape relative to global trends, enabling companies to position PDX services competitively and capitalize on the country's emerging research capabilities.
- Investment Opportunities : Identify growth opportunities in Mexico's preclinical research sector, including infrastructure development, technology adoption, and collaboration potential with North American pharmaceutical companies.
- Regional Expansion Planning : Leverage Mexico-specific market data to plan regional expansion strategies across Latin America, using Mexico as a strategic hub for oncology research and drug development services.
- Stakeholder Insights : Access comprehensive analysis of key stakeholders including Mexican CROs, academic institutions, and pharmaceutical partners to inform business development and partnership decisions.
Frequently asked questions
What is the current market size of PDX models in Mexico?
Mexico's Patient Derived Xenografts market is valued at USD 1.26 million in 2025 and is expected to grow to USD 1.73 million by 2030.
What is the projected growth rate for PDX models in Mexico?
Mexico's PDX models market is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2030.
Which sectors are driving PDX adoption in Mexico?
Academic research institutions, contract research organizations (CROs), and multinational pharmaceutical companies are the primary drivers of PDX model adoption in Mexico.
Why is Mexico becoming attractive for PDX research?
Mexico offers cost-competitive research services, strategic geographic positioning in the Americas, growing research infrastructure, and increasing international collaborations that make it attractive for PDX model development.
What factors will support PDX market growth in Mexico through 2030?
Government initiatives in cancer research, private sector investments, rising awareness of precision oncology, and partnerships between Mexican and international research organizations will support PDX market growth in Mexico.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report